Drake & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Drake & Associates's LLY Position: Q2 2026 in Review
Drake & Associates increased its Eli Lilly (LLY) stake by 82% in Q2 2026, buying an estimated $558K and bringing the position to 1,213 shares worth $1.45M. The position accounts for 0.25% of the portfolio, ranked #30.
Drake & Associates first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Drake & Associates held 1,213 shares of Eli Lilly worth $1.45M as of Q2 2026.
- Drake & Associates bought 546 Eli Lilly shares in Q2 2026, an estimated $558K.
- Eli Lilly made up 0.25% of Drake & Associates's portfolio in Q2 2026, its #30 holding.
- Drake & Associates first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
- 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Drake & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.